Recently, the Canadian federal government passed regulations that change how the Patented Medicine Prices Review Board (PMPRB) will regulate maximum prices for patented medicines for every sale in Canada. The regulatory changes include revisions to the basket of comparator countries (removing the US and Switzerland and adding six jurisdictions with…
Subscribe Membership Required
You must be a Subscribe member to access this content.
Already a member? Log in here
